<DOC>
	<DOCNO>NCT00853632</DOCNO>
	<brief_summary>The purpose study demonstrate long term safety effectiveness Carpentier-Edwards® PERIMOUNT Magna Mitral Valves patient undergo mitral valve replacement without concomitant procedure require cardiopulmonary bypass .</brief_summary>
	<brief_title>Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol</brief_title>
	<detailed_description>This prospective , single-arm , multi-center study conduct US outside US ( OUS ) . Approximately 250 subject plan enrol obtain long term data 101 subject 8 year post implant Magna mitral valve . Of 250 , approximately 38 ( 15 % ) anticipate simultaneous aortic mitral replacement . Subject enrollment start US obtain FDA approval post market study . Assessments obtain preoperative operative visit , postoperatively discharge , six month , 1-year annually thereafter minimum 8 year . Subject 's demographic ( date birth , sex ) , physical assessment ( heart rate , height , weight , systolic diastolic blood pressure ) , New York Heart Association ( NYHA ) functional class , cardiac rhythm , cardiovascular medical history/risk factor , non-cardiovascular condition , previous cardiovascular procedures/interventions , antithromboembolic lipid lower medication coagulation profile . Blood data require subject preoperatively 6 month . Echocardiographic evaluation require subject preoperatively , discharge , 6 month ( 3-6 month ) , 1 , 2 , 4 , 6 , 8 year follow-ups . A QOL survey ( EQ-5D ) complete subject pre-operatively 6-month follow-up visit .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>The patient require , indicate preoperative evaluation , replacement mitral valve . The patient sign date subject inform consent form prior surgery . The patient expect survive surgery discharge . The patient geographically stable agrees attend followup assessment . The patient 18 year old . The patient know noncardiac lifethreatening disease , limit patient 's life expectancy 1 year . The patient present active endocarditis within last 3 month . The patient pregnant lactating . The patient intravenous drug abuser . The patient currently prison inmate . The patient currently participate study investigational drug device . The patient require replacement native prosthetic tricuspid pulmonic valve . The patient require replacement native prosthetic aortic valve prosthesis commercially available CarpentierEdwards PERIMOUNT Valve ( i.e . model 2700 , 2700TFX , 2800 , 2800TFX , 2900 , 3000 , 3000TFX , 3300TFX ) * . The patient previously enrol study . The patient prior aortic , tricuspid and/or pulmonary valve surgery , include implantation bioprosthetic valve mechanical valve remain situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mitral valve</keyword>
	<keyword>pericardial bioprostheses</keyword>
	<keyword>PERIMOUNT</keyword>
	<keyword>bovine pericardial leaflet</keyword>
	<keyword>mitral valve replacement</keyword>
	<keyword>mitral valve regurgitation</keyword>
	<keyword>Heart valve disease</keyword>
</DOC>